FDA Approves New Breast Cancer Drug Cutting Progression by 40 per cent The US Food and Drug Administration has approved a new treatment for advanced breast cancer, with the progression risk falling by 40 per cent. Pharmaceutical giant Eli Lilly has …

… . Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608 Relay …

A breakthrough therapy for advanced breast cancer also works well in the early stages, allegedly improving survival outcomes for patients. According to the pharmaceutical company Lilly Oncology, a phase 3 clinical trial has now confirmed that the …

Alright, folks, let’s talk about a stock that’s lighting up the market like a Fourth of July fireworks show! Celcuity Inc. (NASDAQ: CELC) is stealing the spotlight today, and for good reason. As of this writing, the stock is skyrocketing in pre-market …

Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our …

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live longer, research reveals. The combination treatment is made up of two targeted drugs: …

A three-drug 'breakthrough' treatment for aggressive, advanced breast cancer can prolong survival by a quarter, a pivotal trial has found. Thousands of women could benefit after tests showed the method was more effective than the current NHS …

Natural compounds unveiled at major cancer conference show promise in eliminating breast cancer stem cells without harming healthy tissue AUSTIN, TX, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- A groundbreaking discovery in the fight …

A pill that stops the spread of advanced breast cancer has been approved for routine NHS use in a “triumph” for British science. About 1,100 women each year will benefit from capivasertib, which is taken as a twice-daily tablet, and is proven to double the …

The AIM-traded firm said the study, an interventional phase one clinical trial, investigated the use of the FDA-approved drug digoxin in treating metastatic breast cancer patients. It said the Parsortix system was instrumental in selecting patients for the …